Treatments for metastatic castration-sensitive prostate cancer
Castration-sensitive prostate cancer (CSPC) is cancer that is being controlled by keeping the testosterone level as low as would be expected if the testicles were removed (called the castrate level). Metastatic prostate cancer is prostate cancer that has spread to other parts of the body.
The goal of treatment is to help you live longer and try to improve your quality of life. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.
Treatment options for metastatic castration-sensitive prostate cancer may include a combination of the following:
- hormone therapy
- radiation therapy
- surgery to relieve symptoms
- treatments for bone metastases
- watchful waiting
Hormone therapy @(Model.HeadingTag)>
Hormone therapy is the main treatment for metastatic castration-sensitive prostate cancer. It decreases the levels of hormones or blocks certain hormones to slow the growth and spread of cancer cells. Hormone therapy may be given along with radiation therapy or chemotherapy.
Hormone therapies may be used on their own or combined and include:
luteinizing hormone-releasing hormone (LHRH)agonist
- an LHRH antagonist
- an anti-androgen
- an androgen synthesis inhibitor
- an orchiectomy (surgery to remove the testicles)
Find out more about hormone therapy for prostate cancer.
Radiation therapy @(Model.HeadingTag)>
Radiation therapy may be offered for metastatic hormone-sensitive prostate cancer. It uses high-energy rays or particles to destroy cancer cells.
External radiation therapy is the type of radiation therapy most often used. It is often given together with hormone therapy. External radiation therapy may be used:
- to relieve urinary (peeing) problems caused by the tumour
- to relieve pain where the cancer has spread to the bones (called bone metastases)
Find out more about radiation therapy for prostate cancer.
A transurethral resection of the prostate (TURP) removes part of the prostate through the urethra. It may be done to help relieve urinary problems caused by an enlarged prostate pressing on the urethra.
Find out more about surgery for prostate cancer.
Chemotherapy may be offered for metastatic castration-sensitive prostate cancer. It uses anticancer drugs to destroy cancer cells.
Docetaxel combined with darolutamide (Nubeqa) and prednisone are the drugs used most often. They are used along with hormone therapy.
Find out more about chemotherapy for prostate cancer.
Treatments for bone metastases @(Model.HeadingTag)>
When prostate cancer spreads to other parts of the body, it most often spreads to the bones. The most common treatments for prostate cancer that has spread to the bones are:
- bisphosphonates, such as zoledronic acid (Zometa)
- denosumab (Xgeva), which is a type of
monoclonal antibody therapy
- corticosteroids, such as prednisone and dexamethasone
- external radiation therapy
- systemic radiation therapy with radium-223 dichloride (Xofigo)
- a procedure to stabilize a collapsed bone (called kyphoplasty)
- pain medicines
Find out more about bone metastases, including treatments and supportive therapies.
Watchful waiting @(Model.HeadingTag)>
Watchful waiting may be a treatment option for older men (who aren't expected to live long and whose cancer is not causing symptoms) or for those who are unable to have treatment because of other health conditions.
Find out more about watchful waiting for prostate cancer.
If you can’t have or don’t want cancer treatment @(Model.HeadingTag)>
You may want to consider a type of care to make you feel better without treating the cancer itself. This may be because the cancer treatments don’t work anymore, they’re not likely to improve your condition or they may cause side effects that are hard to cope with. There may also be other reasons why you can’t have or don’t want cancer treatment.
Talk to your healthcare team. They can help you choose care and treatment for advanced cancer.
Clinical trials @(Model.HeadingTag)>
Talk to your doctor about clinical trials open to people with prostate cancer in Canada. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.
Expert review and references
Peter Chung, MBChB, FRCPC
Krista Noonan, MD, FRCPC
American Cancer Society. Treating Prostate Cancer. 2019: https://www.cancer.org/.
American Society of Clinical Oncology. Prostate Cancer. 2020: https://www.cancer.net/.
Tracy, CR. Prostate Cancer. eMedicine/Medscape; 2020: https://emedicine.medscape.com/.
Garnick MB (ed.). Harvard Medical School 2015 Annual Report on Prostate Diseases. 2015.
Mir MC, Stephenson AJ . Expectant management of localized prostate cancer. Nargund VH, Raghavan D, Sandler HM (eds.). Urological Oncology. Springer; 2015: 41: 719-730.
PDQ® Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ®)–Patient Version. Bethesda, MD: National Cancer Institute; 2020: https://www.cancer.gov/.
PDQ® Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ®)–Health Professional Version. Bethesda, MD: National Cancer Institute; 2020: https://www.cancer.gov/.
National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 3.2020) . 2020 .
Princess Margaret Cancer Centre. Princess Margaret Cancer Centre Clinical Practice Guidelines: Prostate Cancer. 2015: http://www.uhn.ca/.
Zelefsky MJ, Morris MJ, Eastham JA. Cancer of the prostate. DeVita VT Jr., Lawrence TS, Rosenberg SA, eds.. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019: 70: 1087-1136.
Parker C, Castro E, Fizazi K et al . Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up . Annals of Oncology . 2020 : 31(9): 1119-1134 .
Raghavan D, Chai Seungjean C, Mahoney J . Castrate resistant prostate cancer: Systemic chemotherapy and a system problem. Nargund VH, Raghavan D, Sandler HM (eds.). Urological Oncology. Springer; 2015: 49: 835-845.
Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, et al . The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC) . Canadian Urological Association Journal . 2015 .
Saad F, Aprikian A, Finelli A, et al . 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) . Canadian Urological Association Journal . 2019 : 13(10):307-14 .
So AI, Chi KN, Danielson B, et al . Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer . Canadian Urological Association Journal . 2020 : 14(2): 17–23 .
James ND, Sydes MR, Clarke NW, et al . Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. Elsevier; 2016: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800035/pdf/main.pdf.
Sweeney CJ, Chen YH, Carducci M, et al . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine. 2015: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562797/pdf/nihms719565.pdf.
Alberta Health Services. Advanced/Metastatic Prostate Cancer - Clinical Practice Guideline GU-010 - Version 2 . 2020 : https://www.albertahealthservices.ca/.